Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Average Price Target of $21.00

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $21.00.

Several research analysts have commented on AMRX shares. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. Leerink Partners assumed coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 price target on the stock. Oppenheimer assumed coverage on Amneal Pharmaceuticals in a research note on Wednesday. They set an “outperform” rating and a $27.00 price target on the stock. JPMorgan Chase & Co. restated an “overweight” rating and issued a $22.00 price objective on shares of Amneal Pharmaceuticals in a report on Wednesday, August 26th. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director John Kiely sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the sale, the director owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the transaction, the executive vice president owned 253,390 shares in the company, valued at approximately $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 413,016 shares of company stock valued at $7,216,567. Company insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Tidal Investments LLC boosted its position in Amneal Pharmaceuticals by 39.1% during the 2nd quarter. Tidal Investments LLC now owns 31,723 shares of the company’s stock valued at $549,000 after acquiring an additional 8,914 shares in the last quarter. WINTON GROUP Ltd raised its position in shares of Amneal Pharmaceuticals by 21.3% in the 2nd quarter. WINTON GROUP Ltd now owns 144,816 shares of the company’s stock worth $2,507,000 after acquiring an additional 25,435 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth $139,000. Arizona State Retirement System lifted its stake in shares of Amneal Pharmaceuticals by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 44,011 shares of the company’s stock worth $762,000 after purchasing an additional 837 shares during the last quarter. Finally, Allianz Asset Management GmbH purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth $225,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $19.77 on Friday. The firm has a market cap of $6.31 billion, a PE ratio of 40.35, a price-to-earnings-growth ratio of 2.34 and a beta of 1.24. The firm’s 50 day simple moving average is $18.07 and its 200-day simple moving average is $15.39. Amneal Pharmaceuticals has a one year low of $9.56 and a one year high of $21.17. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities analysts predict that Amneal Pharmaceuticals will post 0.94 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.